Puma Biotech Beats Q2 Estimates, Retires All Debt, but Loses Key Patent Appeal
PBYI has more than doubled off its 52-week low of $3.05.
Summary
Puma Biotechnology reported Q2 revenue of $56.5M and adjusted EPS of $0.20, beating estimates, while fully repaying its debt. However, the company lost its appeal in the AstraZeneca patent case, eliminating a major potential cash inflow, and shareholders rejected a warrant extension for the CEO.
Key Events · Earnings and Guidance · PBYI
-
Q2 Earnings Beat
Revenue of $56.5M (+7.8% YoY) and adjusted EPS of $0.20, exceeding the single-analyst estimate of $0.04. Product revenue grew 8.9% to $53.6M on higher volume and price.
-
Debt Fully Repaid
On May 4, 2026, the company paid $11.5M to retire the remaining Athyrium Notes, eliminating all long-term debt. Interest expense fell to $0.2M in Q2 from $1.8M a year ago.
-
AstraZeneca Patent Appeal Lost
On July 9, 2026, the Federal Circuit affirmed the invalidity of the '314 and '162 patents, ending the appeal. A prior $107.5M jury award and potential ongoing royalties are now void.
-
CEO Warrant Extension Rejected
At the June 11, 2026 annual meeting, stockholders did not approve extending CEO Auerbach's warrant for 2.1M shares at $16. The warrant now expires October 4, 2026.
Analysis · PBYI · Life Sciences
A strong second quarter saw Puma Biotechnology post $56.5M in revenue and adjusted EPS of $0.20, easily surpassing the lone analyst estimate of $0.04. The balance sheet strengthened further with the full repayment of Athyrium debt, wiping out a $102M obligation and all associated interest costs. Yet the quarter's gains were overshadowed by a critical legal setback: the Federal Circuit affirmed the invalidity of key patents in the AstraZeneca litigation, extinguishing a potential $107.5M damages award and future royalties. In a separate governance matter, stockholders rejected an extension of CEO Auerbach's warrant, which now expires in October 2026. Meanwhile, R&D spending jumped 32% as the company advances alisertib, and four board members adopted 10b5-1 plans, signaling potential insider sales ahead.
At the time of this filing, PBYI was trading at $8.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $413.3M. The 52-week trading range was $3.05 to $8.75. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.